Inhibikase Therapeutics, Inc. (IKT) Ownership
IKT ownership summary
as of October 18, 2026- Institutions
- 89.7% of shares outstanding
- Insiders
- 6.09% of shares outstanding
- Shares outstanding
- 139.5M
- Float
- 107.1M shares available to trade
- Short interest
- 21.68% 19.4M shares short
- Days to cover
- 34.84 short interest up 4.9% vs prior month
- Institutions 89.72%
- Insiders 6.09%
- Other investors 4.19%
IKT top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Sands Capital Ventures, LLC | 9.33% | 13.0M | $21.5M | — | June 30, 2026 |
| 2 | Soleus Capital Management, L.P. | 7.79% | 10.9M | $17.9M | — | June 30, 2026 |
| 3 | Trails Edge Capital Partners, LP | 6.49% | 9.1M | $14.9M | +993,973 (+12.3%) | June 30, 2026 |
| 4 | Fairmount Funds Management LLC | 6.18% | 8.6M | $14.2M | — | June 30, 2026 |
| 5 | BlackRock Inc | 5.57% | 7.8M | $12.8M | +1.5M (+23.2%) | June 30, 2026 |
| 6 | Kalehua Capital Management LLC | 5.48% | 7.6M | $12.6M | +1.1M (+17.7%) | June 30, 2026 |
| 7 | ADAR1 Capital Management LLC | 5.29% | 7.4M | $12.2M | +780,633 (+11.8%) | June 30, 2026 |
| 8 | Blackstone Inc | 4.26% | 5.9M | $9.8M | — | June 30, 2026 |
| 9 | Siren, L.L.C. | 4.19% | 5.8M | $9.7M | — | June 30, 2026 |
| 10 | Nantahala Capital Management, LLC | 3.87% | 5.4M | $8.9M | +2.7M (+100.0%) | June 30, 2026 |
| 11 | COMMODORE CAPITAL LP | 3.87% | 5.4M | $8.9M | — | June 30, 2026 |
| 12 | Vanguard Capital Management, LLC | 3.54% | 4.9M | $8.1M | +484,689 (+10.9%) | June 30, 2026 |
| 13 | Millennium Management LLC | 2.89% | 4.0M | $6.6M | +1.1M (+37.6%) | June 30, 2026 |
| 14 | Saturn V Capital Management LLC | 2.77% | 3.9M | $6.4M | +5,611 (+0.1%) | June 30, 2026 |
| 15 | Spruce Street Capital LP | 2.57% | 3.6M | $5.9M | — | June 30, 2026 |
| 16 | Squadron Capital Management LLC | 2.15% | 3.0M | $5.0M | −500,000 (−14.3%) | June 30, 2026 |
| 17 | Geode Capital Management, LLC | 1.87% | 2.6M | $4.3M | +436,943 (+20.1%) | June 30, 2026 |
| 18 | State Street Corp | 1.37% | 1.9M | $3.2M | +223,285 (+13.2%) | June 30, 2026 |
| 19 | SummitTX Capital, L.P | 1.28% | 1.8M | $2.9M | +255,726 (+16.8%) | June 30, 2026 |
| 20 | Integral Health Asset Management, LLC | 0.97% | 1.4M | $2.2M | — | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 11 holders added 9.6M shares and 1 cut 500K.
IKT top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.70% | 3.8M | $6.2M | — | August 31, 2026 |
| 2 | iShares Russell 2000 ETF | 2.49% | 3.5M | $5.7M | −40,064 (−1.1%) | September 30, 2026 |
| 3 | Fidelity Small Cap Index | 0.95% | 1.3M | $2.2M | −1,627 (−0.1%) | July 31, 2026 |
| 4 | iShares Russell 2000 Value ETF | 0.94% | 1.3M | $2.2M | +1,978 (+0.2%) | September 30, 2026 |
| 5 | Vanguard Russell 2000 ETF | 0.50% | 696K | $1.1M | +13,800 (+2.0%) | August 31, 2026 |
| 6 | iShares Micro-Cap ETF | 0.32% | 453K | $746,876 | −3,122 (−0.7%) | September 30, 2026 |
| 7 | Fidelity Extended Market Index | 0.31% | 428K | $705,608 | −2,298 (−0.5%) | August 31, 2026 |
| 8 | Schwab Small Cap Index | 0.21% | 294K | $485,107 | — | August 31, 2026 |
| 9 | iShares Russell 2000 Small-Cap Idx Instl | 0.17% | 237K | $390,710 | — | August 31, 2026 |
| 10 | CREF Total Global Stock Account R3 | 0.15% | 216K | $355,988 | — | July 31, 2026 |
| 11 | ALPS Medical Breakthroughs ETF | 0.13% | 184K | $302,858 | — | September 30, 2026 |
| 12 | Fidelity Small Cap Value Index | 0.13% | 176K | $290,915 | +7,199 (+4.3%) | July 31, 2026 |
| 13 | JPMorgan Small Cap Value I | 0.12% | 167K | $275,824 | — | August 31, 2026 |
| 14 | Fidelity Nasdaq Composite Index | 0.12% | 163K | $269,290 | +91,371 (+127.2%) | August 31, 2026 |
| 15 | Nuveen Small Cap Blend Idx R6 | 0.12% | 162K | $266,937 | — | August 31, 2026 |
| 16 | Fidelity Total Market Index | 0.11% | 148K | $243,725 | +4,366 (+3.0%) | August 31, 2026 |
| 17 | Stt Strt SPDR® Russell2000 US SmCapETF | 0.10% | 141K | $232,317 | +6,740 (+5.0%) | August 31, 2026 |
| 18 | Fidelity Series Total Market Index | 0.09% | 129K | $212,413 | +2,775 (+2.2%) | August 31, 2026 |
| 19 | Avantis US Small Cap Equity ETF | 0.09% | 120K | $197,627 | +784 (+0.7%) | September 30, 2026 |
| 20 | Xtrackers Russell 2000 ETF 1C | 0.09% | 119K | $195,985 | +5,125 (+4.5%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
IKT insider transactions
latest 1| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2024-10-21 | Arvind Kush | Buy | $1.37 | 145,000 | $198,650 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
IKT shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns IKT
Institutional investors own 89.7% of Inhibikase Therapeutics's shares and insiders 6.09%. The largest holder is Sands Capital Ventures, LLC with 9.33% of the shares (13.0M), as of June 30, 2026. Among the top 20 institutions, 11 added shares and 1 reduced their stake in the latest filings. Short interest is 21.68% of the float, or 34.84 days of average trading volume. The share count rose 5,375.3% since 2017.
Related: IKT analyst forecast, IKT key metrics. See the IKT stock overview for the latest quote and news.
IKT ownership FAQ
Who owns the most Inhibikase Therapeutics stock?
The largest shareholders of Inhibikase Therapeutics are Sands Capital Ventures, LLC (9.33%), Soleus Capital Management, L.P. (7.79%), Trails Edge Capital Partners, LP (6.49%), Fairmount Funds Management LLC (6.18%), BlackRock Inc (5.57%).
What percentage of Inhibikase Therapeutics is owned by institutions?
Institutions hold 89.7% of Inhibikase Therapeutics's shares outstanding; insiders hold 6.09%.
Which funds own Inhibikase Therapeutics?
The largest fund holders of Inhibikase Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (2.70%), iShares Russell 2000 ETF (2.49%), Fidelity Small Cap Index (0.95%), iShares Russell 2000 Value ETF (0.94%), Vanguard Russell 2000 ETF (0.50%).
What is Inhibikase Therapeutics's short interest?
19.4M shares of Inhibikase Therapeutics were sold short, 21.68% of the float; at the average daily volume it would take 34.84 days to cover.
Are insiders buying or selling Inhibikase Therapeutics?
Of the latest 1 reported insider transactions in Inhibikase Therapeutics (since October 21, 2024), 1 were purchases and 0 were sales.
How many shares of Inhibikase Therapeutics are outstanding?
Inhibikase Therapeutics has 139.5M shares outstanding, of which 107.1M are in the public float.